英國批准首款口服減肥藥物
UK Approves First Oral Weight Loss Medication
Updated at: June 15, 2026 at 02:30 AM
2026年6月11日，英國在醫學上取得了一項重大突破，藥品和保健產品管理局(MHRA)批准了首款用於體重管理的口服GLP-1受體激動劑。
On June 11, 2026, the UK made a significant medical breakthrough with the Medicines and Healthcare products Regulatory Agency (MHRA) approving the first oral GLP-1 receptor agonist for weight management.
這款名為Wegovy的全新每日口服司美格魯肽(semaglutide)錠劑，為那些比起每週注射更偏好服用藥丸的患者提供了另一種選擇。
This new daily tablet version of semaglutide, branded as Wegovy, offers an alternative for patients who prefer pills over the previously required weekly injections.
此項發展預計將使肥胖症的治療變得更容易取得，且對許多人來說不再那麼令人望而生畏。
This development is expected to make obesity treatment more accessible and less daunting for many.
雖然目前僅能透過私人處方取得，但該藥物適用於BMI值在30以上的成人，或是BMI值介於27至30之間且患有與體重相關健康問題的患者。
While currently available only through private prescription, the drug is intended for adults with a BMI of 30 or above, or those with a BMI of 27 to 30 with weight-related health conditions.
雖然效果顯著——臨床試驗顯示在64週內平均體重減輕了13.6%——但患者仍應預期會出現噁心或腹瀉等常見的胃腸道副作用。
While effective—clinical trials showed a 13.6% average weight loss over 64 weeks—patients should expect common gastrointestinal side effects like nausea or diarrhea.
衛生當局亦警告民眾切勿從未受監管的管道購買藥物，因為偽藥會帶來嚴重風險。
Health authorities also caution against purchasing medications from unregulated sources, as counterfeit drugs pose serious risks.
此項批准代表著肥胖症治療的一大進步，前提是必須透過專業藥局管道安全地進行管理。
This approval represents a major step forward in obesity care, provided it is managed safely through professional pharmacy channels.
